

Cite this: *Chem. Sci.*, 2026, 17, 4191

All publication charges for this article have been paid for by the Royal Society of Chemistry

Lanthanide complexes with acetophenone-based push-pull antennas as efficient MRI and two-photon microscopy imaging probes

Baptiste Chartier,^{ab} Luke Marchetti,^c Lamiaa M. A. Ali,^d Dina Akl,^e Guillaume Micouin,^e Akos Banyasz,^e Sandra Mème,^c Didier Boturyn,^b Sule Erbek,^{fg} Véronique Martel-Frchet,^{fg} Alexei Grichine,^f Olivier Maury,^g Magali Gary-Bobo,^{gd} Célia S. Bonnet^{gc} and Olivier Sénéque^{ga}

Lanthanide(III) (Ln^{3+}) complexes possess unique magnetic and optical properties that make them ideal candidates for the development of multimodal MRI and optical probes. However, the requirements for developing effective MRI and optical probes are difficult to meet within a single ligand. Here, we propose the use of a DOTA-type ligand equipped with a π -extended acetophenone moiety that (i) serves as a coordinating moiety to form stable Ln^{3+} complexes, (ii) acts as a 2P-excitable push-pull antenna to sensitize Eu^{3+} luminescence, and (iii) displays a carboxylate handle offering high water solubility and enabling conjugation to biomolecules for targeting purposes. We show that the Ln^{3+} complexes obtained are kinetically inert and thermodynamically stable. The Gd^{3+} complex exhibits positive *in vivo* characteristics with good contrast in all organs and rapid renal clearance, while the corresponding Eu^{3+} complex has excellent one-photon and two-photon (2P) absorption properties enabling high-quality *in vivo* 2P microscopy imaging of zebrafish embryos or *in vitro* imaging of living cells when conjugated to a cell-penetrating peptide.

Received 7th September 2025
Accepted 17th December 2025

DOI: 10.1039/d5sc06902e

rsc.li/chemical-science

Introduction

Over the past number of decades, lanthanide complexes have been implemented with great success in various modalities in the field of biological imaging. Luminescent lanthanide complexes possess many advantageous properties for optical techniques, such as narrow emission bands at fixed wavelengths that are specific to each lanthanide, long luminescence lifetimes, and resistance to photobleaching.^{1,2} Indeed, there are numerous examples of luminescent lanthanide complexes, such as those containing Eu^{3+} , Tb^{3+} or Yb^{3+} , being exploited for not only cellular imaging³⁻⁸ but also for detection of various analytes.⁹⁻¹² Magnetic resonance imaging (MRI) is an imaging technique, endowed with unlimited tissue depth penetration

and excellent spatiotemporal resolution. The exploitation of Gd^{3+} -based contrast agents (CAs) in MRI has allowed for improved diagnostic accuracy¹³ and having the option to incorporate targeting moieties into the CA¹⁴ or render it “responsive”,^{12,15,16} enabling the selective detection of various biologically relevant species – including but not limited to cations,¹⁷⁻¹⁹ extracellular proteins,²⁰ and neurotransmitters.²¹

These two imaging modalities are not without their own drawbacks, however. While luminescence techniques display high sensitivity, they suffer from low macroscopic resolution and often require the integration of a cell-internalization vector, such as a peptide, to penetrate into living cells. Meanwhile, MRI has high macroscopic resolution but low sensitivity, requiring high concentrations of CAs to be detected. In recent years, the development of imaging probes active in both modalities has seen increased traction.²²⁻³¹ By incorporating complementary imaging modalities within a single molecular design, one could achieve non-invasive, real-time monitoring with high sensitivity and resolution, effectively overcoming the limitations of individual imaging modalities.^{24,27,28} This would also have the benefit of complementary imaging at different scales, enabling monitoring of cellular processes and the anatomical context in real time.

Lanthanide complexes are particularly well-suited for these applications because of their different optical and magnetic properties across the series while still maintaining similar

^aUniv. Grenoble Alpes, CNRS, CEA, IRIG, LCBM (UMR 5249), F-38000 Grenoble, France. E-mail: olivier.seneque@univ-grenoble-alpes.fr

^bUniv. Grenoble Alpes, CNRS, DCM (UMR 5250), F-38000 Grenoble, France

^cCentre de Biophysique Moléculaire, CNRS (UPR 4301), Université d'Orléans, F-45041 Orléans, France. E-mail: celia.bonnet@cnrs.fr

^dIBMM, Univ Montpellier, CNRS, ENSCM, F-34000 Montpellier, France. E-mail: magali.garybobo@umontpellier.fr

^eUniv Lyon, ENS de Lyon, CNRS UMR 5182, Laboratoire de Chimie, Lyon F-69342, France

^fUniv. Grenoble Alpes, INSERM U1209, CNRS UMR 5309, Institute for Advanced Biosciences, F-38000 Grenoble, France

^gEPHE, PSL Research University, 4-14 Rue Ferrus, 75014 Paris, France



coordination properties and chemical reactivities. However, the development of pairs of lanthanide complexes relying on the same ligand, but displaying both MRI and luminescent activities is not without its own set of hurdles, either. MRI CAs require at least one inner-sphere coordinated water molecule to the Gd^{3+} -center for efficient reduction of the T_1 relaxation time of water protons. This can be seen as incompatible with luminescent complexes which usually display a saturated coordination sphere, as directly coordinated water molecules quench lanthanide luminescence due to non-radiative deactivation.

Moreover, luminescent lanthanide complexes suffer from low molar absorption coefficients with values of about 1 to 5 $M^{-1} cm^{-1}$, due to the Laporte rule that forbids the f-f transition. Nevertheless, this can be bypassed by the well-documented 'antenna effect', whereby a chromophore is implemented close to the lanthanide.^{2,12,32} This chromophore should efficiently absorb light, typically in the ultraviolet (UV) range, followed by subsequent energy transfer to the lanthanide, thus allowing for the sensitization of the lanthanide and resulting luminescence emission. It is important to note that the use of UV light to excite the antenna is problematic, as UV light has not only been proven to be cytotoxic, but can also be absorbed and scattered by biological tissues. An alternative to this excitation pathway is the use of a two-photon (2P) absorption process that allows for the simultaneous absorption of two photons, with half the energy required for a normal excitation with one photon.³³⁻³⁶ This method allows for a bathochromic shift of the excitation wavelength, moving from the UV to the red or near infrared (NIR) region, which is known to be less toxic and less scattered by biological tissues. Unlike MRI, one of the main drawbacks of luminescence is its low tissue penetration. 2P excitation in the NIR region allows deeper tissue penetration, thus compensating for the limitation of fluorescence imaging.^{37,38}

We have recently developed 2P excitable Ln^{3+} probes that were used successfully for 2P microscopy of live cells.³⁹⁻⁴³ These probes are based on a DO3Apic ligand that saturates the Ln^{3+} coordination sphere, precluding their use as MRI CAs. With the aim to design an octadentate Ln^{3+} chelator that leaves a single water molecule in the coordination sphere of the Ln^{3+} and features a 2P absorbing antenna, we identified DO3A-AP in the literature. This ligand was first reported to bind Eu^{3+} and sensitize its luminescence through the acetophenone antenna.⁴⁴ $EuDO3A-AP$ is mono-hydrated and shows a Eu^{3+} luminescence quantum yield of 0.058 upon excitation in the acetophenone absorption band at 265 nm. The absorption could be red-shifted by introducing electron-rich methoxy⁴⁴ or triazole⁴⁵ groups in the *para*-position of the acetophenone or by substituting the phenyl-ketone by other aryl-ketones (aryl = naphthyl, carbazolyl or phenantrenyl).⁴⁶ The relaxometric properties of $GdDO3A-AP$ and related derivatives with hydroxy substituents were recently described.^{47,48} However, the *in vivo* MRI (with Gd^{3+} as Ln^{3+}) or *in vitro/in vivo* microscopy imaging (with Eu^{3+}) capacities of the $LnDO3A-AP$ system were never explored.

Based on this, we wanted to push the advantage and propose for the first time a monohydrated Ln^{3+} complex for both high resolution 2P microscopy, with Eu^{3+} as Ln^{3+} , and MRI, with Gd^{3+} . We present here $DO3A-AP^{ArOR}$ (Fig. 1), a ligand derived from DO3A-AP bearing an antenna with strong push-pull capabilities providing 2P absorption properties and a reactive handle for the facile incorporation of a cell-penetrating peptide. The coordination sphere remains unsaturated, allowing for one water molecule in the inner-sphere, providing the opportunity for its use as an MRI contrast agent. The photophysical properties of the Eu^{3+} complex were investigated, alongside its 2P excitation properties, and compared to those of the previously




Fig. 1 Structure of (A) complexes $LnDO3A-AP^{ArOR}$ (Ln = Eu or Gd), $EuDO3Apic^{ArOR}$, $EuDO3Apic^{CCArOR}$, $GdDO3A-AP$, $GdHPDO3A$, $GdDOTA$, $GdDO3A$ and $Vasovist$, all discussed in the text and (B) conjugate $mTAT[EuDO3A-AP^{ArOR}]$.



described non-hydrated picolinate analogues $\text{EuDO3A}^{\text{ArOR}}$ and $\text{EuDO3A}^{\text{CCArOR}}$.^{39,43} Despite its coordinated water molecule, $\text{EuDO3A-AP}^{\text{ArOR}}$ shows good luminescence properties. The relaxometric properties of the Gd^{3+} complex were characterized by variable temperature ^{17}O NMR experiments and nuclear magnetic relaxation dispersion. The complex also displays very high kinetic inertness. These positive features allow for the *in vivo* use of the Gd^{3+} complex as an efficient MRI contrast agent and the Eu^{3+} complex as a luminescent probe for 2P microscopy in zebrafish. A cell-penetrating peptide, mTAT, was conjugated to the antenna which allowed for internalization of the complex to the cytosol of live HeLa cells, visualized by 2P microscopy. Therefore, this versatile design based on a Ln^{3+} complex allows *in vivo* MRI in mice and 2P microscopy on zebrafish and high quality cell imaging by 2P microscopy.

Results and discussion

Synthesis of the ligand and its lanthanide complexes

The synthetic pathway for the preparation of the acetophenone-based Ln^{3+} complexes is depicted in Fig. 2A. The synthesis starts with the alkylation of $\text{DO3A}(t\text{Bu})_3$ **1** (ref. 49) with 2-bromo-1-(4-iodophenyl)ethan-1-one **2** in MeCN to give compound **3** in 94% yield. A Miyaura–Suzuki coupling between **3** and boronic ester **4** (ref. 43) in DMF with polymer-bound $\text{Pd}(\text{PPh}_3)_4$ as a catalyst affords the *t*Bu-protected ligand **5** in 56% yield. After acidolysis of the *t*Bu esters in a TFA/DCM mixture, metalation with Eu^{3+} or Gd^{3+} salt in water (pH 7) followed by HPLC purification and freeze-drying gives complexes $\text{LnDO3A-AP}^{\text{ArOR}}$ in 80–90% yield. Note that these compounds are sensitive to basic conditions, which can cause *N*-dealkylation of the acetophenone arm. The detailed synthetic procedures and NMR, HPLC and mass spectrometry characterization of these compounds are given in the SI.

Photophysical properties

The photophysical properties of the $\text{EuDO3A-AP}^{\text{ArOR}}$ complex were investigated in phosphate-buffered saline (PBS, pH 7.4). The absorption spectrum of $\text{EuDO3A-AP}^{\text{ArOR}}$ shows a broad structureless band in the UV region with a maximum at 342 nm (λ_{max}) extending up to 403 nm ($\lambda_{\text{cut-off}}$), which is assigned to an intra-ligand charge transfer transition (ILCT) within the antenna from the anisole donor to the coordinated carbonyl acceptor moieties (Fig. 3). This absorption is red-shifted by *ca.* 35 nm and 10 nm (Fig. S8) compared to the picolinate analogues $\text{EuDO3A}^{\text{ArOR}}$ and $\text{EuDO3A}^{\text{CCArOR}}$ (Fig. 1) with alkoxy-phenyl-picolinate and alkoxy-phenyl-ethynyl-picolinate antennas, respectively.^{39,43} The molar absorption coefficient of $\text{EuDO3A-AP}^{\text{ArOR}}$ was determined to be $20\,000\ \text{M}^{-1}\ \text{cm}^{-1}$ at λ_{max} (Fig. S9) similar to $\text{EuDO3A}^{\text{ArOR}}$ ($21\,000\ \text{M}^{-1}\ \text{cm}^{-1}$)⁴³ and $\text{EuDO3A}^{\text{CCArOR}}$ ($21\,000\ \text{M}^{-1}\ \text{cm}^{-1}$).³⁹ Upon excitation into the ILCT band at 340 nm, the Eu^{3+} emission is observed with $^5\text{D}_0 \rightarrow ^7\text{F}_j$ transitions ($j = 0, 1, 2, 3$ and 4) at 580, 595, 615, 650 and 700 nm, respectively. The excitation spectrum ($\lambda_{\text{em}} = 615\ \text{nm}$) matches well with the absorption spectrum, confirming that the alkoxy-phenyl-acetophenone antenna sensitizes Eu^{3+} luminescence. The Eu^{3+} luminescence decay could be perfectly fitted with a mono-exponential giving a lifetime value of 0.53 (2) ms (Fig. S10), which is about half that of the picolinate analogues $\text{EuDO3A}^{\text{ArOR}}$ and $\text{EuDO3A}^{\text{CCArOR}}$ (1.1 ms) with a saturated Eu^{3+} coordination sphere (hydration number $q = 0$).^{39,43} The lifetime remains unchanged upon degassing the solution. In PBS prepared with D_2O , the Eu^{3+} decay lifetime was 1.49 ms. According to Parker's equation, a hydration number q of 1.2 (2) was calculated from the lifetimes in H_2O and D_2O ,³⁰ indicating that a single water molecule stands in the coordination sphere of Eu^{3+} . This is in agreement with the literature on Ln^{3+} complexes of DO3A-AP ligands.^{44–48} The Eu^{3+} emission quantum yield, Φ_{Eu} , is 0.075 (Fig. S11), again almost half that of the




Fig. 2 Synthetic pathway for (A) $\text{EuDO3A-AP}^{\text{ArOR}}$ and $\text{GdDO3A-AP}^{\text{ArOR}}$ and (B) $\text{mTAT[EuDO3A-AP}^{\text{ArOR}}]$. In (B), * denotes standard side chain protecting groups.






Fig. 3 (A) 1P spectroscopy: normalized absorption (black solid lines), excitation (black dashed lines; $\lambda_{em} = 615$ nm) and emission (red solid lines; $\lambda_{ex} = 340$ nm) spectra of EuDO3A-AP^{ArOR} in PBS, pH 7.4. (B and C) 2P spectroscopy: (B) quadratic power dependence of the Eu³⁺ emission ($\lambda_{ex} = 700$ nm) for EuDO3A-AP^{ArOR} in PBS pH 7.4; data were fitted using $I = A \times P^n$ yielding $n = 2.01$; (C) 2P absorption spectrum (red) measured in PBS superimposed to the wavelength-doubled 1P absorption spectrum (black).

picolinate analogues (0.14 and 0.17 for EuDO3Apic^{ArOR} and EuDO3Apic^{CCArOR}, respectively).^{39,43} The energy of the alkoxy-phenyl-acetophenone antenna triplet state, T_1 , is $21\,100\text{ cm}^{-1}$ (determined from the onset of the phosphorescence emission of GdDO3A-AP^{ArOR} at 77 K), which is 2000 cm^{-1} below that of the picolinate analogue (Fig. S12).⁴³ However, the antenna T_1 state remains high enough to prevent efficient back energy transfer from the Eu³⁺ 5D_0 excited state. In the end, EuDO3A-AP^{ArOR} is half as bright as its picolinate analogue because of the presence of one Eu³⁺-bound water molecule.

The 2P absorption properties of EuDO3A-AP^{ArOR} were determined by the two-photon excited fluorescence method. First, the quadratic dependence of the emitted Eu³⁺ intensity on laser power was checked under excitation at 700 nm with a Ti:sapphire laser (Fig. 3B). Then, the 2P absorption spectrum was measured. It matches nicely the wavelength-doubled 1P absorption spectrum (Fig. 3C). At 720 nm, the wavelength used in 2P microscopy experiments (*vide infra*), the 2P absorption cross-section, σ_{2P} , is 36 GM (1 GM = $10^{-50}\text{ cm}^4\text{ s photon}^{-1}$), similar to that of the alkoxy-phenyl-ethynyl-picolinate antenna (35 GM)⁵¹ and *ca.* 10 times higher than that measured for an Eu³⁺ complex with a methoxy-phenyl-picolinamide antenna.⁴² At 720 nm, the 2P brightness, $B_{2P} = \sigma_{2P} \times \Phi_{Eu}$, of EuDO3A-AP^{ArOR} is 2.7 GM.

Relaxometric characterization of GdDO3A-AP^{ArOR}

Since EuDO3A-AP^{ArOR} has a hydration number q of 1, its Gd³⁺ analogue appears to be a good candidate for MRI imaging. In




Fig. 4 (A) ^1H NMRD profiles of GdDO3A-AP^{ArOR} (0.88 mM) at 25 °C (blue), 37 °C (orange), and 50 °C (red). (B) Temperature dependence of the ^{17}O reduced transverse relaxation rates (top) and chemical shifts (bottom) of GdDO3A-AP^{ArOR} at 9.4 T (9 mM). The dotted lines represent the simultaneous fit of the experimental data points.

order to characterize the efficacy of GdDO3A-AP^{ArOR} and relate this to the microscopic parameters that govern the efficacy (relaxivity) of the complex, nuclear magnetic relaxation dispersion (NMRD) profiles, in combination with variable temperature ^{17}O NMR experiments, were recorded. The NMRD profiles were recorded within the range of 0.01–600 MHz, at three different temperatures: 25, 37, and 50 °C (Fig. 4A). As temperature increased, the r_1 values decreased, indicating that the rotational correlation time is the limiting factor in the relaxivity, which is expected with a small molecular complex. The relaxivity at 20 MHz, 25 °C is $5.4\text{ mM}^{-1}\text{ s}^{-1}$, consistent with the values found under the same conditions for GdHPDO3A ($4.6\text{ mM}^{-1}\text{ s}^{-1}$)⁵² and GdDO3A-AP ($5.1\text{ mM}^{-1}\text{ s}^{-1}$).⁴⁷

The reduced transverse relaxation rates ($1/T_{2r}$) were measured as a function of temperature to determine the water exchange rate, k_{ex} , while the reduced chemical shifts give access to the number of coordinated water molecules on the Gd³⁺ complex. The ^{17}O -reduced transverse relaxation rates increase (up to *ca.* 333 K), followed by a plateau (Fig. 4B). The shape of the curve indicates that there are at least two isomers present in solution, most likely the SAP and TSAP coordination isomers which display greatly different water exchange rates, as seen



with GdHPDO3A,⁵² GdDOTA bisamide derivatives^{53,54} or GdDO3A-AP.⁴⁷ Thusly, a ¹H NMR study was performed (700 MHz at 288, 298, and 318 K) to determine the ratio between the SAP and TSAP isomers of EuDO3A-AP^{ArOR} in solution (Fig. S14). The SAP isomer is found to be the main isomer as already reported for the majority of DOTA-based complexes.⁵⁵ The ratio of SAP : TSAP is found to be 80 : 20, which is consistent with complexes reported in the literature with a similar coordination sphere.^{46,47} Importantly, this ratio is constant over the range of temperature studied. The reduced chemical shifts measured are consistent with a monohydrated complex in solution, in accordance with the luminescence measurements on the Eu³⁺ complex.

The NMRD profiles, transverse ¹⁷O relaxation rates, and ¹⁷O chemical shifts were fitted simultaneously using Solomon-Bloembergen and Morgan (SBM) theory, while considering the relative populations of the two isomers in solution, to yield the microscopic parameters that govern the proton relaxivity of the complex (Tables 1 and S1). The NMRD profiles were fitted in the range 4–600 MHz, where the effect of the electron spin relaxation, which is not well described by the SBM theory alone, is negligible, and the SBM approach gives reliable information on dynamic processes like the water exchange rate and rotational correlation time for small complexes.^{56,57}

Under the reasonable assumption that the rotational correlation time (τ_R) is the same for both SAP and TSAP species, a value of 134 ps is found. This value is higher than that of GdHPDO3A (65 ps) and GdDO3A-AP (100 ps), which is consistent with the larger size of GdDO3A-AP^{ArOR}. The fitting of the data yields $k_{ex} = 0.49 \times 10^6 \text{ s}^{-1}$ for the SAP isomer and $k_{ex} = 18 \times 10^6 \text{ s}^{-1}$ for the TSAP isomer. This is a well-known phenomenon, whereby the increased steric hindrance around the Gd³⁺-center of the TSAP isomer results in a faster water exchange rate. It was previously observed that the introduction of a ketone pendant arm resulted in slow water exchange rates.^{47,58} In this case, the exchange rates of the SAP and TSAP isomers are even slower than those of GdDO3A-AP. This could be explained by the electronic effects of the benzene on the acetophenone, which decreases the electronic density on the ketone; therefore the steric crowding around Gd³⁺. In such complexes with positive activation entropy (dissociatively activated mechanism), this results in a lower water exchange rate.⁵⁹

Due to the presence of the hydrophobic biphenyl moiety, the complex could be prone to aggregation processes. Paramagnetic Relaxation Enhancements (PRE) measurements were




Fig. 5 T_1 -Weighted phantom images in mouse serum with GdDO3A-AP^{ArOR} and GdDOTA (0.3 mM) at room temperature. Images were acquired at 7 T using a spin echo sequence with TE = 10 ms and TR = 400 ms. The intensities are respectively 3.89×10^4 , 3.97×10^4 and 1.04×10^4 for GdDO3A-AP^{ArOR}, GdDOTA, and serum.

performed at 60 MHz and 25 °C as a function of concentration (Fig. S15). A linear trend is observed, which demonstrates no aggregation of the complex in the concentration range studied (ca. 80 μM –8 mM).

The incorporation of a lipophilic group into a Gd³⁺-based contrast agent is a well-established method to promote non-covalent interactions between the CA and human serum albumin (HSA). This interaction has several advantages, such as increased relaxivity of the CA, mainly due to the increased rotational correlation time of the chelate, and a prolonged vascular retention time. Considering that biphenyl moieties have been leveraged multiple times to this effect, we considered that the biphenyl antenna present in DO3A-AP^{ArOR} could possibly interact with HSA in this manner. Thus, the relaxivity of GdDO3A-AP^{ArOR} in the presence of 0.6 mM HSA was measured at 60 MHz, 25 °C. An increase of ca. 110% in relaxivity was observed in the presence of HSA ($r_1 = 11.4 \text{ mM}^{-1} \text{ s}^{-1}$ vs. $r_1 = 5.38 \text{ mM}^{-1} \text{ s}^{-1}$ in HEPES buffer).

To further evaluate the potential of this complex as a contrast agent, T_1 -weighted phantom images were recorded at 7 T, where the relaxivity of GdDO3A-AP^{ArOR} was measured in mouse blood serum and compared to that of GdDOTA, a Gd³⁺-based CA used clinically (Fig. 5). While GdDO3A-AP^{ArOR} did not retain its enhanced relaxivity at higher field strengths, it did display a similar signal intensity (3.89×10^4) to the clinically used GdDOTA (3.97×10^4) at 7 T, 25 °C (0.3 mM in mouse serum).

Stability

Given the *in vitro* potential of the system both in terms of luminescence and relaxivity, we wanted to assess its *in vivo* applicability. However, it is of prime importance to check the thermodynamic stability and kinetic inertness of the system

Table 1 The best-fit parameters obtained from the simultaneous fitting of the NMRD profiles at 298 K, 310 K, and 323 K, and the transverse ¹⁷O relaxation rates and chemical shifts as a function of temperature at 9.4 T

	Isomer	GdDO3A-AP ^{ArOR}	GdDO3A-AP ⁴⁷	GdHPDO3A ⁵²
r_1 ($\text{mM}^{-1} \text{ s}^{-1}$) 20 MHz, 25 °C		5.4	5.1	4.6
k_{ex}^{298} (10^6 s^{-1})	SAP	0.49 (3)	0.83	1.56
ΔH^\ddagger (kJ mol^{-1})	SAP	55 (3)	50	53
ΔS^\ddagger ($\text{kJ mol}^{-1} \text{ K}^{-1}$)	SAP	+49	+36	+52
k_{ex}^{298} (10^6 s^{-1})	TSAP	18 (3)	40	112
ΔH^\ddagger (kJ mol^{-1})	TSAP	42 (8)	27	15
τ_R^{298} (ps)		134 (3)	100	65



prior to *in vivo* use. Macrocyclic lanthanide complexes based on DOTA or DOTA-monoamide systems are known to display high thermodynamic stability and kinetic inertness.⁶⁰ In this case, one ketone function is coordinating the Ln³⁺. Therefore, we first investigated the thermodynamic stability and kinetic inertness of EuDO3-AP^{ArOR} by competitions with DTPA at pH 7.4. EuDO3A-AP^{ArOR} was mixed with DTPA (1, 10 and 100 eq.) at pH 7.4 in PBS and the Eu³⁺ emission intensity was monitored after 24 h. At 1 : 1 and 1 : 10 EuDO3A-AP^{ArOR}/DTPA ratios, the Eu³⁺ emission intensity remained unchanged (Fig S16). A slight decrease in Eu³⁺ intensity was observed for a 1 : 100 ratio. This is indicative of a high thermodynamic stability or kinetic inertness. Under more challenging conditions to assess the kinetic inertness and compare to other macrocyclic complexes, EuDO3-AP^{ArOR} was dissolved in HCl 1 M. The emission spectrum is the same as that at pH 7.4 (Fig. S17A), indicating that the coordination sphere of the emissive Eu³⁺ species is not altered by the low pH. Under these conditions, the complex fully dissociates (Fig. S17B). Given the very high proton concentration, the dissociation follows a pseudo-first order kinetics, and the dissociation rate is proportional to the total concentration of the complex [LnL]_t, with *k*_{obs} being the pseudo-first order rate constant:

$$-\frac{d[\text{LnL}]_t}{dt} = k_{\text{obs}}[\text{LnL}]_t$$

The dissociation half-life and *k*_{obs} values determined in 1 M HCl are presented in Table 2. The *k*_{obs} is one order of magnitude higher than that of GdDOTA,⁶¹ but two to three orders of magnitude lower than that of the other macrocyclic compounds (GdDO3A⁶² or EuDO3Apic⁶³). Importantly, it is one order of magnitude lower than that of commercially available GdHPDO3A.⁶⁴ The half-life in 1 M HCl is 5.3 h, which demonstrates the strong inertness of EuDO3-AP^{ArOR}.

In vivo MRI biodistribution in mice

Encouraged by the *in vitro* results and the very high inertness of the complex, an *in vivo* MRI study was then carried out, where five healthy mice were injected with GdDO3A-AP^{ArOR} (100 μmol kg⁻¹). After intravenous administration of the contrast agent, an immediate increase in signal intensity was observed, with the signal enhancement peaking two minutes after injection for all organs (Fig. 6). The kidneys experienced the greatest signal enhancement over other organs. This indicates that the CA is cleared *via* the kidneys, with a negligible portion *via* the liver,

Table 2 Rate constants characterizing the dissociation of complexes determined in 1 M HCl at 298 K and half-life under the same conditions

	<i>k</i> _{obs} (s ⁻¹)	<i>t</i> _{1/2} (min)
EuDO3A-AP ^{ArOR}	(3.6 ± 0.2) × 10 ⁻⁵	320 ± 20
GdDOTA ⁶¹	1.8 × 10 ⁻⁶	6418
GdDO3A ⁶²	2.3 × 10 ⁻²	0.5
EuDO3Apic ⁶³	2.0 × 10 ⁻³	5.7
GdHPDO3A ⁶⁴	2.6 × 10 ⁻⁴	44




Fig. 6 (A) *T*₁-weighted MR images recorded at 9.4 T of healthy mice pre-injection (left) and 2, 30 and 40 minutes post i.v. injection of GdDO3A-AP^{ArOR} at 100 μmol kg⁻¹, (B) % of MRI signal enhancement in the spleen, liver, kidneys and muscle, 2, 5, 10, 20, 30, 40 and 50 minutes post i.v. injection of GdDO3A-AP^{ArOR} at 100 μmol kg⁻¹ (*n* = 5, ±SD). (C) Gd content in the blood, spleen, liver, kidneys, and pancreas measured by ICP-OES 1 h after injection of GdDO3A-AP^{ArOR} (blue), GdDOTA (grey), or Vasovist (orange). Data are presented in % of injected dose by organ mass (*n* = 5, ±SD).

which is expected for a small molecular complex. The clearance is fast as the signal enhancement in the main organs (liver, spleen and muscle) is negligible 50 min post-injection. *Ex vivo* bi-distribution was also studied 1 h post injection and the Gd³⁺ content of various organs was measured *ex vivo* by Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) (Fig. 6). Less than 3% of the injected dose per organ gram is found, showing a good elimination of the contrast agent after one hour. Interestingly, the Gd content one hour post injection is intermediate to that found for GdDOTA and Vasovist,⁶⁵ a blood-pool agent. This is consistent with the *in vitro* results showing some HSA binding and a certainly longer circulation time than GdDOTA, but shorter than Vasovist. The excellent stability and inertness of GdDO3A-AP^{ArOR} and successful MRI experiments prompted us to evaluate the potential of the Eu³⁺ analogue



EuDO3A-AP^{ArOR} for *in vivo* 2P microscopy imaging in zebrafish embryos.

In vivo 2P microscopy of zebrafish embryos

The use of zebrafish (*Danio rerio*) embryos is increasingly recognized as an alternative to testing on small mammals.^{66,67} Although imaging of zebrafish embryos with fluorescent probes is classical,⁶⁸ to our knowledge, examples of 2P zebrafish imaging with Ln³⁺ probes are scarce.^{7,69} First, the toxicity of EuDO3A-AP^{ArOR} in zebrafish embryos was studied at the single cell stage (see the SI for details). The development of embryos was observed at different time points (24, 48, 72, 96 and 120 h) post-injection. The viability was based on the morphology and the presence of heartbeat. Malformation including pericardial oedema, yolk sac oedema, spinal curvature and tail malformation was recorded. Dead embryos were removed immediately. The results shown in Fig. 7 demonstrate the mild toxicity of EuDO3A-AP^{ArOR} *in vivo* (Fig. 7c). At 72 hpi (hours post-injection), an increase in the death rate of the EuDO3A-AP^{ArOR} injected group (25%) compared to the non-injected group (5%) was observed. Furthermore, an increase in the hatching rate in the PBS and EuDO3A-AP^{ArOR} injected groups (~70%) compared to the non-injected group (25%) was recorded. EuDO3A-AP^{ArOR} did not induce higher morphological abnormalities than the non-injected or PBS injected group. The toxicity profile of EuDO3A-AP^{ArOR} remains constant from 72 hpi until 120 hpi.

Then, 2P microscopy imaging of zebrafish embryos was performed under 720 nm excitation with spectral detection for 3 h after intravenous injection of EuDO3A-AP^{ArOR} (see the SI for




Fig. 7 Casper zebrafish embryo development expressed as percentages of chorionated, hatched, malformed and dead (A) without injection or after 1 nL of injection of (B) PBS or (C) EuDO3A-AP^{ArOR} (1 mM) at the single cell stage. The observation was carried out after 24, 48, 72, 96 and 120 hpi. The total number of embryos is 20, 15 and 20 for non-injected, PBS and EuDO3A-AP^{ArOR} respectively. Data are presented as mean \pm SEM. (D) Representative images of the microscopic observation of embryos at 48 and 96 hpi using the microscope Zeiss Stemi 508.




Fig. 8 (A) 2P microscopy imaging of 72 hours post-fertilization of casper zebrafish embryos intravenously injected with 10 nL of EuDO3A-AP^{ArOR} (1 mM) and observed 3 h after injection at 720 nm ($n = 5$ embryos). Scale bar 500 μ m. (B) Mean emission spectra in area outlined in blue and green in panel (A.) (C) Linear unmixing of autofluorescence and the Eu³⁺ signal.

details). As shown in Fig. 8A, the luminescence signal was collected with a 570–640 bp filter and a long integration time of 131 μ s per pixel. The emission was detected in the heart, intersegmental vessels, caudal vein, caudal artery, primary head sinus and the inner optic circle. In contrast, in the control (no Eu³⁺ probe injected), the luminescence was detected mainly in the yolk, which usually shows high autofluorescence. In injected embryos, spectral detection (Fig. 8B) allowed for the discrimination of the broad autofluorescence signal with a maximum at *ca.* 460 nm and the Eu³⁺ emission with characteristic peaks at 580 nm and 620 nm. As expected, the latter was not detected in the control. Linear unmixing of the autofluorescence and Eu³⁺ signals is shown in Fig. 8C. EuDO3A-AP^{ArOR} is clearly distributed in the cardiovascular circulatory system. Finally, the viability of embryos injected with EuDO3A-AP^{ArOR} was 80% after 3 days post-injection, confirming its low toxicity. Therefore, EuDO3A-AP^{ArOR} is suitable to provide high-quality 2P images in zebrafish.

Preparation and characterization of the TAT conjugate

The *in vivo* applicability of the complex is well established in both MRI and luminescence to probe the extracellular environment. However, for bioimaging applications, it can be interesting to specifically vectorize the probe, for example, towards cancer cells or to make it cell-permeable in order to probe the intracellular environment and obtain complementary information. This is generally achieved by coupling the probe to a peptide or a protein that provides recognition properties. Here, we choose to demonstrate the applicability of EuDO3A-AP^{ArOR} for 2P microscopy at the cell level by conjugating it to the well-known TAT cell penetrating peptide.^{41,42,70} The preparation of TAT conjugates with LnDO3Apic complexes, which were



described previously, relies on the coupling of a protected macrocyclic ligand to the peptide on resin, followed by (i) acidic cleavage from the resin and deprotection (side chains and ligand), (ii) HPLC purification and (iii) metalation with Ln^{3+} . Here we opted for a more straightforward strategy, directly coupling the Ln^{3+} complex to the peptide on resin (Fig. 2B). The peptide was elongated on Rink Amide resin using solid phase peptide synthesis following classical procedures for the Fmoc/*t*Bu strategy. The *N*-terminal lysine was orthogonally protected with an alloc group. After selective removal of this group on resin using Pd^0 , EuDO3A-AP^{ArOR} was coupled to the peptide *via* its carboxylate handle using HATU/DIEA activation for 2 h. After resin cleavage and protecting group removal using TFA/ H_2O /TIS, the conjugate was purified by HPLC and freeze-dried. The Eu^{3+} complex resisted the TFA treatment and the acidic HPLC conditions ($\text{H}_2\text{O}/\text{MeCN}$ mixture with 0.1% TFA, pH *ca.* 2) and no Eu^{3+} release was observed, further validating the high inertness of the complex. Proper conjugation through the carboxylate handle on the electron donating group of the antenna was confirmed by mass spectrometry and Eu^{3+} luminescence properties.

The spectroscopic properties of mTAT[EuDO3A-AP^{ArOR}] are very similar to those of the parent Eu^{3+} complex (Fig. S13), with an identical absorption band, the same Eu^{3+} emission spectrum, which attests that the conjugation has not altered the Eu^{3+} coordination sphere, and identical Eu^{3+} luminescence lifetime (0.50 (2) ms) and quantum yield ($\Phi_{\text{Eu}} = 0.077$) within the error margin. All this indicates that conjugation to the TAT peptide has no influence on the emission properties of EuDO3A-AP^{ArOR}.

In vitro 2P microscopy on living HeLa cells

In vitro imaging was attempted with live HeLa cells incubated with a mixture of mTAT[EuDO3A-AP^{ArOR}] and dFFLIPTAT, a dimeric cell penetrating peptide (sequence: (CFFLIPRKKRRQRRRG)₂, dimerized *via* a disulfide bond) that helps TAT monomers such as mTAT[LnL] probes to enter live cells.^{41,42,71} Before conducting 2P microscopy on live HeLa cells, the cytotoxicity of the conjugate in co-incubation with dFFLIPTAT (1.5 μM) was examined using the MTT assay (Fig. S18). After 48 h of cell proliferation, no cytotoxicity was observed when the conjugate was incubated at 5 μM and 10 μM .

For microscopy experiments, HeLa cells were incubated with mTAT[EuDO3A-AP^{ArOR}] (5 μM) and dFFLIPTAT (1.5 μM) for 1 h before washing and imaging on a 2P microscope under 720 nm excitation using an APD (avalanche photodiode) for sensitive detection and a 580–680 nm bandpass filter to collect Eu^{3+} emission Fig. 9A. The DIC (differential interference contrast) image shows HeLa cells with a phenotype of living cells in agreement with the MTT assay. The luminescence channel shows stained cells with diffuse red emission within the whole cell, typical of successful cytosolic delivery of the probe.^{40,42} The cell-to-cell intensity heterogeneity is a common feature of probes based on cell penetrating peptides.^{40,42,72,73} In order to confirm that the luminescence channel collects Eu^{3+} emission, a spectral image was recorded using the PMT array of the 2P




Fig. 9 2P microscopy imaging ($\lambda_{\text{ex}} = 720$ nm) of living HeLa cells incubated 1 h with mTAT[EuDO3A-AP^{ArOR}] (5 μM) and dFFLIPTAT (1.5 μM) in RPMI medium. (A) Left panel: differential interference contrast (DIC) image; middle panel: luminescence image recorded with 575–680 nm bp APD detection; right panel: merge. Scale bars correspond to 10 μm . (B) 2P-excited emission spectra (detected with a PMT array and averaged over the whole cell surface) of the cells outlined in red and blue and background (green). (C) Eu^{3+} luminescence decay in the cell outlined in red.

microscope. Fig. 9B shows the mean emission spectra of cells, recorded over the area outlined in red and blue in the DIC image. For the $^5\text{D}_0 \rightarrow ^7\text{F}_1$, $J = 1$ and 2, emission bands of Eu^{3+} emission are unambiguously observed between 575 and 630 nm. The Eu^{3+} luminescence lifetime was measured in cells using the TSLIM method (Fig. 9C).⁷⁴ A value of 0.57 ± 0.03 ms (average over 15 measurements in three distinct cells) was found, similar to the one recorded in solution. This was surprising because with other Eu^{3+} or Tb^{3+} probes featuring chelators that saturate the Ln^{3+} coordination sphere, we have always measured lifetimes *ca.* 30% shorter in cells than in the cuvette.^{40,75} This shorter lifetime was proposed to be the consequence of additional de-excitation pathways in the cell *via* protein co-factors. In the present case, the higher lifetime suggests a change in the average hydration number of Eu^{3+} , *i.e.* a partial replacement of the Eu^{3+} -bound H_2O by coordinating amino acid side chains of a protein or small molecule. Note that under similar incubation conditions (1 h, 5 μM probe), the non-conjugated complex EuDO3A-AP^{ArOR} is not detected within cells. Addition of DMSO (up to 5%) in the incubation medium to permeabilize membranes did not improve uptake. This demonstrates the value of conjugating the probe to a cell penetrating peptide. To sum up, despite its Eu^{3+} -bound water molecule, EuDO3A-AP^{ArOR} conjugated to the TAT cell



penetrating peptide allows 2P microscopy of live cells and gives high-quality images of live cells.

Conclusions

In this article, we have demonstrated that adding a π -conjugated extension to the acetophenone moiety of ligand DO3A-AP provides a luminescent Eu^{3+} complex, $\text{EuDO3A-AP}^{\text{ArOR}}$, with excellent 2P absorption properties compared to its picolinate analogue. Despite an Eu^{3+} -bound water molecule, which quenches Eu^{3+} emission and lowers luminescence properties, this complex has sufficiently good luminescence properties to make it suitable for *in vivo* 2P imaging of zebrafish and live cell 2P imaging. Compared to the picolinate analogue, the water molecule bound to Ln^{3+} proves to be an advantage, allowing MRI imaging *in vivo* with the Gd analogue, $\text{GdDO3A-AP}^{\text{ArOR}}$. This complex is therefore able to probe the extracellular environment *in vivo* both in MRI, with Gd^{3+} , and 2P microscopy imaging, with Eu^{3+} . Several DO3A- or DOTA-based ligand systems were already described to elaborate by simple Ln^{3+} exchange on both luminescent Eu^{3+} or MRI-active Gd^{3+} probes, with predictable MRI properties due to the DO3A/DOTA scaffold.^{26–29} However, they were used in luminescence microscopy imaging with UV excitation. The system described here integrates a push–pull antenna that permits 2P excitation in the NIR region, which is less damaging and allows better tissue penetration. The strong 2P absorption properties of this system provided for instance excellent quality microscopy images of zebrafish embryos. Finally, another advantage of this system is its pending carboxylate, which allows straightforward conjugation of $\text{LnDO3A-AP}^{\text{ArOR}}$ complexes to biomolecules such as peptides. This has been exemplified here with a TAT conjugate, a cell-penetrating peptide, allowing high-quality living cell microscopy images to be obtained following 2P absorption despite the presence of the water molecule on Ln^{3+} . Therefore, $\text{LnDO3A-AP}^{\text{ArOR}}$ complexes have great potential and versatility for the safe development of efficient agents for MRI and 2P microscopy imaging.

Ethical statement

All animal experiments were carried out in accordance with the guidelines for animal experiments and under permission number 54201, from the French “Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation”.

Author contributions

Conceptualization: O. S., C. S. B., O. M., and M. G.-B.; investigation: B. C., L. M., L. M. A. A., D. A., G. M., S. M., S. E., V. M.-F., A. G., and O. S.; validation: O. S., C. S. B., M. G.-B., O. M., A. B., S. M. A. G., V. M.-F., and D. B.; writing (original draft): B. C., L. M., L. M. A. A., O. S., C. S. B., and M. G.-B.; writing (review & editing): all authors. visualization: O. S., C. S. B., B. C., L. M., and L. M. A. A.

Conflicts of interest

There are no conflicts to declare.

Data availability

The data supporting this article have been included as part of the supplementary information (SI). Supplementary information: procedures for the synthesis of new compounds, 1P and 2P spectroscopy (absorption and luminescence), relaxometry, stability and inertness assays by luminescence, protocols for MRI experiments, toxicity assays and 2P microscopy of zebrafish embryos, cell culture, toxicity assays and 2P microscopy. See DOI: <https://doi.org/10.1039/d5sc06902e>.

Acknowledgements

Agnès Pallier is acknowledged for performing ICP experiments. The authors thank the MO2VING platform for spectroscopic and MRI experiments. For zebrafish embryo imaging, the authors acknowledge the imaging facility MRI, a member of the France-BioImaging national infrastructure, supported by the French National Research Agency (ANR-10-INBS-04, “Investments for the future”) and also Nicolas Cubedo and Mireille Rossel from the aquatic model facility ZEFIX from MMDN/LPHI/CRBM/IGF. Cell 2P microscopy imaging experiments were done on the Microcell core facility of the Institute for Advanced Biosciences (UGA – Inserm U1209 CNRS 5309). This facility belongs to the IBISA-ISdV platform, a member of the national infrastructure France-BioImaging supported by the French National Research Agency (ANR-10-INBS-04). The authors acknowledge the Agence Nationale de la Recherche [LANTEN project (ANR-21-CE29-0018) and the Zinc-Espionage project (ANR-22-CE44-0041)], the Labex ARCANE and CBH-EUR-GS (ANR-17-EURE-0003) and the CEA FOCUS Biomarqueurs for financial support.

References

- 1 J.-C. G. Bünzli and S. V. Eliseeva, in *Lanthanide Luminescence*, ed P. Hänninen and H. Härmä, Springer Berlin Heidelberg, 2011, pp. 1–45.
- 2 J.-C. G. Bünzli, On the design of highly luminescent lanthanide complexes, *Coord. Chem. Rev.*, 2015, **293**, 19–47.
- 3 C. Alexander, Z. Guo, P. B. Glover, S. Faulkner and Z. Pikramenou, Luminescent Lanthanides in Biorelated Applications: From Molecules to Nanoparticles and Diagnostic Probes to Therapeutics, *Chem. Rev.*, 2025, **125**, 2269–2370.
- 4 M. Wang, Y. Kitagawa and Y. Hasegawa, Current Development of Lanthanide Complexes for Biomedical Applications, *Chem.-Asian J.*, 2024, **19**, e202400038.
- 5 E. Mathieu, A. Sipos, E. Demeyere, D. Phipps, D. Sakaveli and K. E. Borbas, Lanthanide-based tools for the investigation of cellular environments, *Chem. Commun.*, 2018, **54**, 10021–10035.



- 6 G.-Q. Jin, Y. Ning, J.-X. Geng, Z.-F. Jiang, Y. Wang and J.-L. Zhang, Joining the journey to near infrared (NIR) imaging: the emerging role of lanthanides in the designing of molecular probes, *Inorg. Chem. Front.*, 2020, **7**, 289–299.
- 7 N. Hamon, A. Roux, M. Beyler, J.-C. Mulatier, C. Andraud, C. Nguyen, M. Maynadier, N. Bettache, A. Duperray, A. Grichine, S. Brasselet, M. Gary-Bobo, O. Maury and R. Tripier, Cyclen-Based Ln(III) Complexes as Highly Luminescent Bioprobes for In Vitro and In Vivo One- and Two-Photon Bioimaging Applications, *J. Am. Chem. Soc.*, 2020, **142**, 10184–10197.
- 8 R. Sánchez-Fernández, I. Obregon-Gomez, A. Sarmiento, M. E. Vázquez and E. Pazos, Luminescent lanthanide metalloproteins for biomolecule sensing and cellular imaging, *Chem. Commun.*, 2024, **60**, 12650–12661.
- 9 D. Parker, J. D. Fradgley and K.-L. Wong, The design of responsive luminescent lanthanide probes and sensors, *Chem. Soc. Rev.*, 2021, **50**, 8193–8213.
- 10 M. Sy, A. Nonat, N. Hildebrandt and L. J. Charbonnière, Lanthanide-based luminescence biolabelling, *Chem. Commun.*, 2016, **52**, 5080–5095.
- 11 J. M. Zwier, H. Bazin, L. Lamarque and G. Mathis, Luminescent Lanthanide Cryptates: from the Bench to the Bedside, *Inorg. Chem.*, 2014, **53**, 1854–1866.
- 12 M. C. Heffern, L. M. Matosziuk and T. J. Meade, Lanthanide Probes for Bioresponsive Imaging, *Chem. Rev.*, 2014, **114**, 4496–4539.
- 13 J. Wahsner, E. M. Gale, A. Rodríguez-Rodríguez and P. Caravan, Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers, *Chem. Rev.*, 2019, **119**, 957–1057.
- 14 P. Caravan, D. Esteban-Gómez, A. Rodríguez-Rodríguez and C. Platas-Iglesias, Water exchange in lanthanide complexes for MRI applications. Lessons learned over the last 25 years, *Dalton Trans.*, 2019, **48**, 11161–11180.
- 15 P. Yue, T. Nagendraraj, G. Wang, Z. Jin and G. Angelovski, The role of responsive MRI probes in the past and the future of molecular imaging, *Chem. Sci.*, 2024, **15**, 20122–20154.
- 16 M. Liu, J. Gao, Y. Zhang, X. Zhou, Y. Wang, L. Wu, Z. Tian and J.-H. Tang, Recent advances in bioresponsive macrocyclic gadolinium(III) complexes for MR imaging and therapy, *Dalton Trans.*, 2025, **54**, 6741–6777.
- 17 M. V. C. Jordan, S.-T. Lo, S. Chen, C. Preihs, S. Chirayil, S. Zhang, P. Kapur, W.-H. Li, L. M. D. De Leon-Rodríguez, A. J. M. Lubag, N. M. Rofsky and A. D. Sherry, Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, E5464–E5471.
- 18 M. Isaac, A. Pallier, F. Szeremeta, P.-A. Bayle, L. Barantin, C. S. Bonnet and O. Sénèque, MRI and luminescence detection of Zn²⁺ with a lanthanide complex–zinc finger peptide conjugate, *Chem. Commun.*, 2018, **54**, 7350–7353.
- 19 M. Sanadar, K. Zimmerer, H. Martin, A. Pallier, B. Vilenó, P. Faller, A. Sour and C. S. Bonnet, Exploring Bioinspired Ln³⁺ Complexes for Cu²⁺ Detection: Design and Efficacy as MRI Contrast Agents, *Eur. J. Inorg. Chem.*, 2025, **28**, e202500049.
- 20 C. Moreau, T. Lukačević, A. Pallier, J. Sobilo, S. Aci-Sèche, N. Garnier, S. Mème, É. Tóth and S. Lacerda, Peptide-Conjugated MRI Probe Targeted to Netrin-1, a Novel Metastatic Breast Cancer Biomarker, *Bioconjugate Chem.*, 2024, **35**, 265–275.
- 21 F. Oukhatar, S. Mème, W. Mème, F. Szeremeta, N. K. Logothetis, G. Angelovski and É. Tóth, MRI Sensing of Neurotransmitters with a Crown Ether Appended Gd³⁺ Complex, *ACS Chem. Neurosci.*, 2015, **6**, 219–225.
- 22 C. S. Bonnet and É. Tóth, Towards highly efficient, intelligent and bimodal imaging probes: Novel approaches provided by lanthanide coordination chemistry, *C. R. Chim.*, 2010, **13**, 700–714.
- 23 C. S. Bonnet, F. Buron, F. Caille, C. M. Shade, B. Drahos, L. Pellegatti, J. Zhang, S. Villette, L. Helm, C. Pichon, F. Suzenet, S. Petoud and E. Toth, Pyridine-Based Lanthanide Complexes Combining MRI and NIR Luminescence Activities, *Chem.–Eur. J.*, 2012, **18**, 1419–1431.
- 24 B. Song, J. Jiang, H. Yan, S. Huang and J. Yuan, A tumor-targetable probe based on europium(III)/gadolinium(III) complex-conjugated transferrin for dual-modal time-gated luminescence and magnetic resonance imaging of cancerous cells in vitro and in vivo, *J. Mater. Chem. B*, 2023, **11**, 4346–4353.
- 25 S. Laurent, L. Vander Elst, C. Galaup, N. Leygue, S. Boutry, C. Picard and R. N. Muller, Bifunctional Gd(III) and Tb(III) chelates based on a pyridine–bis(iminodiacetate) platform, suitable optical probes and contrast agents for magnetic resonance imaging, *Contrast Media Mol. Imaging*, 2014, **9**, 300–312.
- 26 J. He, C. S. Bonnet, S. V. Eliseeva, S. Lacerda, T. Chauvin, P. Retailleau, F. Szeremeta, B. Badet, S. Petoud, É. Tóth and P. Durand, Prototypes of Lanthanide(III) Agents Responsive to Enzymatic Activities in Three Complementary Imaging Modalities: Visible/Near-Infrared Luminescence, PARACEST-, and T1-MRI, *J. Am. Chem. Soc.*, 2016, **138**, 2913–2916.
- 27 Y. Zhang, X. Ma, H.-F. Chau, W. Thor, L. Jiang, S. Zha, W.-Y. Fok, H.-N. Mak, J. Zhang, J. Cai, C.-F. Ng, H. Li, D. Parker, L. Li, G.-L. Law and K.-L. Wong, Lanthanide-Cyclen–Camptothecin Nanocomposites for Cancer Theranostics Guided by Near-Infrared and Magnetic Resonance Imaging, *ACS Appl. Nano Mater.*, 2021, **4**, 271–278.
- 28 T.-L. Cheung, L. K. B. Tam, W.-S. Tam, L. Zhang, H.-Y. Kai, W. Thor, Y. Wu, P.-L. Lam, Y.-H. Yeung, C. Xie, H.-F. Chau, W.-S. Lo, T. Zhang and K.-L. Wong, Facile Peptide Macrocyclization and Multifunctionalization via Cyclen Installation, *Small Methods*, 2024, e2400006.
- 29 R. Jouclas, S. Laine, S. V. Eliseeva, J. Mandel, F. Szeremeta, P. Retailleau, J. He, J.-F. Gallard, A. Pallier, C. S. Bonnet, S. Petoud, P. Durand and É. Tóth, Lanthanide-Based Probes for Imaging Detection of Enzyme Activities by NIR Luminescence, T1- and ParaCEST MRI, *Angew. Chem., Int. Ed.*, 2024, **63**, e202317728.



- 30 C. A. Foster, D. Sneddon, L. Hacker, E. T. Sarson, M. Robertson, D. Sokolova, L. A. W. Martin, M. F. Allen, A. Khrapichev, K. A. Vincent, E. M. Hammond, S. J. Conway and S. Faulkner, LnDOTA Releasing Probes for Luminescence and Magnetic Resonance Imaging, *Inorg. Chem.*, 2025, **64**, 6640–6647.
- 31 B. Woolley, Y. Wu, L. Xiong, H.-F. Chau, J. Zhang, G.-L. Law, K.-L. Wong and N. J. Long, Lanthanide–tetrazine probes for bio-imaging and click chemistry, *Chem. Sci.*, 2025, **16**, 3588–3597.
- 32 S. I. Weissman, Intramolecular Energy Transfer: The Fluorescence of Complexes of Europium, *J. Chem. Phys.*, 1942, **10**, 214–217.
- 33 M. Pawlicki, H. A. Collins, R. G. Denning and H. L. Anderson, Two-Photon Absorption and the Design of Two-Photon Dyes, *Angew. Chem., Int. Ed.*, 2009, **48**, 3244–3266.
- 34 G. Piszczek, B. P. Maliwal, I. Gryczynski, J. Dattelbaum and J. R. Lakowicz, Multiphoton ligand-enhanced excitation of lanthanides, *J. Fluoresc.*, 2001, **11**, 101–107.
- 35 M. H. V. Werts, N. Nerambourg, D. Pélégrin, Y. L. Grand and M. Blanchard-Desce, Action cross sections of two-photon excited luminescence of some Eu(III) and Tb(III) complexes, *Photochem. Photobiol. Sci.*, 2005, **4**, 531–538.
- 36 A. Picot, A. D'Aleo, P. L. Baldeck, A. Grichine, A. Duperray, C. Andraud and O. Maury, Long-lived two-photon excited luminescence of water-soluble europium complex: Applications in biological imaging using two-photon scanning microscopy, *J. Am. Chem. Soc.*, 2008, **130**, 1532–1533.
- 37 A. D'Aléo, A. Bourdolle, S. Brustlein, T. Fauquier, A. Grichine, A. Duperray, P. L. Baldeck, C. Andraud, S. Brasselet and O. Maury, Ytterbium-Based Bioprobes for Near-Infrared Two-Photon Scanning Laser Microscopy Imaging, *Angew. Chem., Int. Ed.*, 2012, **51**, 6622–6625.
- 38 R. Lengacher, K. E. Martin, D. Śmiłowicz, H. Esseln, P. Lotlikar, A. Grichine, O. Maury and E. Boros, Targeted, Molecular Europium(III) Probes Enable Luminescence-Guided Surgery and 1 Photon Post-Surgical Luminescence Microscopy of Solid Tumors, *J. Am. Chem. Soc.*, 2023, **145**, 24358–24366.
- 39 J.-H. Choi, G. Fremy, T. Charnay, N. Fayad, J. Pécaut, S. Erbek, N. Hildebrandt, V. Martel-Frchet, A. Grichine and O. Sénèque, Luminescent Peptide/Lanthanide(III) Complex Conjugates with Push–Pull Antennas: Application to One- and Two-Photon Microscopy Imaging, *Inorg. Chem.*, 2022, **61**, 20674–20689.
- 40 K. P. Malikidogo, T. Charnay, D. Ndiaye, J.-H. Choi, L. Bridou, B. Chartier, S. Erbek, G. Micouin, A. Banyasz, O. Maury, V. Martel-Frchet, A. Grichine and O. Sénèque, Efficient cytosolic delivery of luminescent lanthanide bioprobes in live cells for two-photon microscopy, *Chem. Sci.*, 2024, **15**, 9694–9702.
- 41 J.-H. Choi, A. Nhari, T. Charnay, B. Chartier, L. Bridou, G. Micouin, O. Maury, A. Banyasz, S. Erbek, A. Grichine, V. Martel-Frchet, F. Thomas, J. K. Molloy and O. Sénèque, Carbazole-Based Eu³⁺ Complexes for Two-Photon Microscopy Imaging of Live Cells, *Inorg. Chem.*, 2025, **64**, 2006–2019.
- 42 B. Chartier, A. Grichine, L. Bridou, A. Nhari, G. Micouin, A. Banyasz, D. Boturny, J. K. Molloy, S. Erbek, V. Martel-Frchet, O. Maury and O. Sénèque, Amido/alkoxy–aryl–aryl–picolinate push–pull antennas for two-photon sensitization of Eu³⁺ luminescence, *Inorg. Chem. Front.*, 2025, **12**, 3313–3323.
- 43 L. Bridou, L. Collobert, K. P. Malikidogo, S. R. Kiraev, M. Hojorot, N. Hamon, A. T. Bui, F. Riobé, A. Banyasz, M. Beyler, R. Tripier, O. Sénèque and O. Maury, Exploring Photophysical Properties and Sensitivity to Oxygen in Anisoyl-Picolinate Antenna Conjugated to Azamacrocycles, *Inorg. Chem.*, 2025, **64**, 13635–13646.
- 44 A. Beeby, L. M. Bushby, D. Maffeo and J. a. G. Williams, Intramolecular sensitisation of lanthanide(III) luminescence by acetophenone-containing ligands: the critical effect of para-substituents and solvent, *J. Chem. Soc.-Dalton Trans.*, 2002, 48–54.
- 45 M. Tropiano, A. M. Kenwright and S. Faulkner, Lanthanide Complexes of Azidophenacyl-DO3A as New Synthons for Click Chemistry and the Synthesis of Heterometallic Lanthanide Arrays, *Chem.-Eur. J.*, 2015, **21**, 5697–5699.
- 46 J. D. Routledge, M. W. Jones, S. Faulkner and M. Tropiano, Kinetically Stable Lanthanide Complexes Displaying Exceptionally High Quantum Yields upon Long-Wavelength Excitation: Synthesis, Photophysical Properties, and Solution Speciation, *Inorg. Chem.*, 2015, **54**, 3337–3345.
- 47 L. Leone, D. Esteban-Gómez, C. Platas-Iglesias, M. Milanesio and L. Tei, Accelerating water exchange in Gd(III)-DO3A-derivatives by favouring the dissociative mechanism through hydrogen bonding, *Chem. Commun.*, 2019, **55**, 513–516.
- 48 L. Leone, S. Camorali, A. Freire-García, C. Platas-Iglesias, D. E. Gomez and L. Tei, Scrutinising the role of intramolecular hydrogen bonding in water exchange dynamics of Gd(III) complexes, *Dalton Trans.*, 2021, **50**, 5506–5518.
- 49 B. Jagadish, G. L. Brickert-Albrecht, G. S. Nichol, E. A. Mash and N. Raghunand, On the synthesis of 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, *Tetrahedron Lett.*, 2011, **52**, 2058–2061.
- 50 A. Beeby, I. M. Clarkson, R. S. Dickins, S. Faulkner, D. Parker, L. Royle, A. S. de Sousa, J. A. G. Williams and M. Woods, Non-radiative deactivation of the excited states of europium, terbium and ytterbium complexes by proximate energy-matched OH, NH and CH oscillators: an improved luminescence method for establishing solution hydration states, *J. Chem. Soc., Perkin Trans.*, 1999, **2**, 493–504.
- 51 S. Mizzoni, S. Ruggieri, A. Sickinger, F. Riobé, L. Guy, M. Roux, G. Micouin, A. Banyasz, O. Maury, B. Baguenard, A. Bensalah-Ledoux, S. Guy, A. Grichine, X.-N. Nguyen, A. Cimarelli, M. Sanadar, A. Melchior and F. Piccinelli, Circularly polarized activity from two photon excitable europium and samarium chiral bioprobes, *J. Mater. Chem. C*, 2023, **11**, 4188–4202.



- 52 D. Delli Castelli, M. C. Caligara, M. Botta, E. Terreno and S. Aime, Combined High Resolution NMR and ^1H and ^{17}O Relaxometric Study Sheds Light on the Solution Structure and Dynamics of the Lanthanide(III) Complexes of HPDO3A, *Inorg. Chem.*, 2013, **52**, 7130–7138.
- 53 S. Zhang, Z. Kovacs, S. Burgess, S. Aime, E. Terreno and A. D. Sherry, DOTA-bis(amide)lanthanide Complexes: NMR Evidence for Differences in Water-Molecule Exchange Rates for Coordination Isomers, *Chem.–Eur. J.*, 2001, **7**, 288–296.
- 54 A. Pagoto, R. Stefania, F. Garelo, F. Arena, G. Digilio, S. Aime and E. Terreno, Paramagnetic Phospholipid-Based Micelles Targeting VCAM-1 Receptors for MRI Visualization of Inflammation, *Bioconjugate Chem.*, 2016, **27**, 1921–1930.
- 55 S. Aime, M. Botta, Z. Garda, B. E. Kucera, G. Tircso, V. G. Young and M. Woods, Properties, Solution State Behavior, and Crystal Structures of Chelates of DOTMA, *Inorg. Chem.*, 2011, **50**, 7955–7965.
- 56 P. H. Fries and E. Belorizky, Electronic relaxation of paramagnetic metal ions and NMR relaxivity in solution: Critical analysis of various approaches and application to a Gd(III)-based contrast agent, *J. Chem. Phys.*, 2005, **123**, 124510.
- 57 P. Miéville, H. Jaccard, F. Reviriego, R. Tripier and L. Helm, Synthesis, complexation and NMR relaxation properties of Gd $^{3+}$ complexes of Mes(DO3A) $_3$, *Dalton Trans.*, 2011, **40**, 4260–4267.
- 58 K. N. Green, S. Viswanathan, F. A. Rojas-Quijano, Z. Kovacs and A. D. Sherry, Europium(III) DOTA-Derivatives Having Ketone Donor Pendant Arms Display Dramatically Slower Water Exchange, *Inorg. Chem.*, 2011, **50**, 1648–1655.
- 59 É. Tóth, L. Helm and A. Merbach, in *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*, ed A. Merbach, L. Helm and É. Tóth, John Wiley & Sons, Ltd, 2013, pp. 25–81.
- 60 E. Brücher, G. Tircsó, Z. Baranyai, Z. Kovács and A. D. Sherry, in *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*, John Wiley and Sons, 2013, pp. 157–208.
- 61 Z. Baranyai, Z. Pálkás, F. Uggeri, A. Maiocchi, S. Aime and E. Brücher, Dissociation Kinetics of Open-Chain and Macrocyclic Gadolinium(III)-Aminopolycarboxylate Complexes Related to Magnetic Resonance Imaging: Catalytic Effect of Endogenous Ligands, *Chem.–Eur. J.*, 2012, **18**, 16426–16435.
- 62 A. Takács, R. Napolitano, M. Purgel, A. C. Bényei, L. Zékány, E. Brücher, I. Tóth, Z. Baranyai and S. Aime, Solution Structures, Stabilities, Kinetics, and Dynamics of DO3A and DO3A-Sulphonamide Complexes, *Inorg. Chem.*, 2014, **53**, 2858–2872.
- 63 M. Regueiro-Figueroa, B. Bensenane, E. Ruscsak, D. Esteban-Gomez, L. J. Charbonniere, G. Tircso, I. Toth, A. de Blas, T. Rodriguez-Blas and C. Platas-Iglesias, Lanthanide dota-like Complexes Containing a Picolinate Pendant: Structural Entry for the Design of Ln(III)-Based Luminescent Probes, *Inorg. Chem.*, 2011, **50**, 4125–4141.
- 64 É. Tóth, R. Király, J. Platzek, B. Radüchel and E. Brücher, Equilibrium and kinetic studies on complexes of 10-[2,3-dihydroxy-(1-hydroxymethyl)-propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate, *Inorganica Chim. Acta*, 1996, **249**, 191–199.
- 65 R. B. Lauffer, D. J. Parmelee, S. U. Dunham, H. S. Ouellet, R. P. Dolan, S. Witte, T. J. McMurry and R. C. Walovitch, MS-325: albumin-targeted contrast agent for MR angiography, *Radiology*, 1998, **207**, 529–538.
- 66 B. Bauer, A. Mally and D. Liedtke, Zebrafish Embryos and Larvae as Alternative Animal Models for Toxicity Testing, *Int. J. Mol. Sci.*, 2021, **22**, 13417.
- 67 T.-Y. Choi, T.-I. Choi, Y.-R. Lee, S.-K. Choe and C.-H. Kim, Zebrafish as an animal model for biomedical research, *Exp. Mol. Med.*, 2021, **53**, 310–317.
- 68 S.-K. Ko, X. Chen, J. Yoon and I. Shin, Zebrafish as a good vertebrate model for molecular imaging using fluorescent probes, *Chem. Soc. Rev.*, 2011, **40**, 2120–2130.
- 69 J. Zheng, Q. Zhan, L. Jiang, D. Xing, T. Zhang and K.-L. Wong, A bioorthogonal time-resolved luminogenic probe for metabolic labelling and imaging of glycans, *Inorg. Chem. Front.*, 2020, **7**, 4062–4069.
- 70 E. Vivès, P. Brodin and B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, *J. Biol. Chem.*, 1997, **272**, 16010–16017.
- 71 J. Allen and J.-P. Pellois, Hydrophobicity is a key determinant in the activity of arginine-rich cell penetrating peptides, *Sci. Rep.*, 2022, **12**, 15981.
- 72 A. Erazo-Oliveras, K. Najjar, L. Dayani, T.-Y. Wang, G. A. Johnson and J.-P. Pellois, Protein delivery into live cells by incubation with an endosomolytic agent, *Nat. Methods*, 2014, **11**, 861–867.
- 73 M. Serulla, P. Anees, A. Hallaj, E. Trofimenko, T. Kalia, Y. Krishnan and C. Widmann, Plasma membrane depolarization reveals endosomal escape incapacity of cell-penetrating peptides, *Eur. J. Pharm. Biopharm.*, 2023, **184**, 116–124.
- 74 A. Grichine, A. Haefele, S. Pascal, A. Duperray, R. Michel, C. Andraud and O. Maury, Millisecond lifetime imaging with a europium complex using a commercial confocal microscope under one or two-photon excitation, *Chem. Sci.*, 2014, **5**, 3475–3485.
- 75 B. Chartier, N. Hamon, D. Akl, A. Sickinger, L. Corne, G. Micouin, A. Banyasz, O. Maury, S. Erbek, V. Martel-Frchet, A. Grichine, M. Beyler, O. Sénèque and R. Tripier, Clickable Pycen-Based Luminescent Lanthanide Complexes: Application to Two-Photon Microscopy, *Chem.–Eur. J.*, 2025, **31**, e02044.

